Biomedical Engineering Reference
In-Depth Information
29. Lu.J..M. Liong, Z.Li, I. Zink, and F.Tamanoi. 2010. Biocompatibility, biodis-
tribution and drug delivery ei ciency of mesoporous silica nanoparticles for
cancer therapy in animals,
Small
6:17941805.
30. Souris, J. S., C. H. Lee, S. H. Cheng, C. T. Chen, C. S. Yang, J. A. Ho, C. Y.
Mou, and L. W. Lo. 2010. Surface charge-mediated rapid hepatobiliary excre-
tion of mesoporous silica nanoparticles.
Biomaterials
31:5564-5574.
31. Global Tuberculosis Control: surveillance, planning, i nancing:WHO report
2008
32. Dye C, Watt C J, Bleed D M, Hosseini S M & Raviglione M C. Evolution
of tuberculosis control and prospects for reducing tuberculosis incidence,
prevalence and deaths globally,
JAMA
, 293 (2005) 2767.
33. Skeiky YA, Sadof JC. Advances in tuberculosis vaccine strategies.
Nature
Reviews Microbiology
, 2006; 4:469-476.
34. Freiden TR, Sterling TR, Munsif SS, Watt CJ, Dye C, Tuberculosis,
h e
Lancet
2003 362(9387):887-899
35. Cornstock GW, Livesay VT, Woolpert SF. h e prognosis of the positive
tuberculin reaction in the childhood and adolescence.
Am J Epidemol
, 1974;
99:131-13
36. Sutherland I: Recent studies in the epidemiology of tuberculosis based on
the risk of being infected with tubercle bacilli.
Adv Tuberc Res
, 1976; 19 :1-63
37. Aagaard C, Dietrich J, Doherty M, Anderson P. TB vaccines: current status
and future perspectives
Immunol Cell Biol
, 2009;87:279-286.
38. Barry C E & Duncan K, Tuberculosis-Strategies towards antiinfectives for a
chronic diseases.
Drug Discov Today
, 1 (2004) 491.
39. Vordermeier HM, Chambers MA, Buddle BM, Pollock JM, Hewinson RG.
Progress in the development of vaccines and diagnostic reagents to control
tuberculosis in cattle.
Vet J
, 2006; 171:229-244.
40. Romano M, Roupie V, Wang XM, Denis O, Jurion F, Adnet PY, Laali R,
Huygen K. Immunogenecity and protective ei cacy of tuberculosis DNA
vaccines combining mycolyltransferase Ag85A and phosphate transport
receptor PstS-3.
Immunology
, 2006; 118:321-332.
41. D'Souza S, Rosseels V, Denis O, Tanghe A, De Smet N, Jurion F, Pall iet K,
Castiglioni N, Vanonckelen A, Wheeler C, Huygen K. Improved tuberculo-
sis DNA vaccines by formulation in cationic lipids.
Infect Immun
, 2002, 70:
3681-3688.
42. Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, Bosio C, Dow S.
Ei cient immunization and cross-priming by vaccine adjuvants containing
TLR3 or TLR9 agonists complexed to cationic liposomes.
J Immunol
, 2006,
176:7335-7345.
43. Fox W, Ellard GA, Mitchison DA: Studies on the treatment of tuberculosis under-
taken by the British Medical Research Council Tuberculosis units, 1946-1986,
with subsequent publications.
Int J Tuberc Lung Dis
1999, 3:S231-S279.
44. World Health Organization. Communicable diseases cluster. Fixed dose
combination tablets for the treatment of tuberculosis, 1999.
